Cargando…

Use of Atorvastatin in Lipid Disorders and Cardiovascular Disease in Chinese Patients

OBJECTIVE: Statins are still underused for the prevention of cardiovascular disease (CVD) in China. Hence, we conducted a systemic review on the pharmacology, clinical efficacy, and adverse events of atorvastatin, as well as on patient adherence. DATA SOURCES: We conducted a systemic search in PubMe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Yi-Cong, Zhao, Xi-Liang, Zhang, Shu-Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4837848/ https://www.ncbi.nlm.nih.gov/pubmed/25591572 http://dx.doi.org/10.4103/0366-6999.149226

Ejemplares similares

Comparing the combination therapy of ezetimibe and atorvastatin with atorvastatin monotherapy for regulating blood lipids: a systematic review and meta-analyse
por: Ai, Cong, et al.
Publicado: (2018)

Atorvastatin and cardiovascular risk in the elderly – patient considerations
por: Acharjee, Subroto, et al.
Publicado: (2008)

Role of Adiponectin in Cardiovascular Diseases Related to Glucose and Lipid Metabolism Disorders
por: Han, Wen, et al.
Publicado: (2022)

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease
por: Xu, Danyan, et al.
Publicado: (2017)

Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives
por: Devabhaktuni, Madhuri, et al.
Publicado: (2009)

Vitamin D Levels and Lipid Response to Atorvastatin
por: Pérez-Castrillón, José Luis, et al.
Publicado: (2010)

Zhibitai and low-dose atorvastatin reduce blood lipids and inflammation in patients with coronary artery disease
por: Zhao, Yuhong, et al.
Publicado: (2017)

The potential of Atorvastatin for chronic lung diseases therapy
por: Tulbah, Alaa S.
Publicado: (2020)

Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence
por: Perez-Calahorra, Sofía, et al.
Publicado: (2019)

Atorvastatin Therapy Modulates Telomerase Activity in Patients Free of Atherosclerotic Cardiovascular Diseases
por: Strazhesko, Irina D., et al.
Publicado: (2016)

Atorvastatin as an adjuvant with betamethasone valerate reduces disease severity and cardiovascular risks in Psoriasis
por: Asad, Farah, et al.
Publicado: (2017)

Impact of the Gut Microbiota on Atorvastatin Mediated Effects on Blood Lipids
por: Zimmermann, Friederike, et al.
Publicado: (2020)

Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial
por: Soedamah-Muthu, Sabita S., et al.
Publicado: (2015)

Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials
por: Colivicchi, Furio, et al.
Publicado: (2015)

Proanthocyanidins Should Be a Candidate in the Treatment of Cancer, Cardiovascular Diseases and Lipid Metabolic Disorder
por: Wang, Tsz Ki, et al.
Publicado: (2020)

Metabolism-involved drug interactions with traditional Chinese medicines in cardiovascular diseases
por: Liang, Ren-Jong, et al.
Publicado: (2022)

Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease
por: Gu, Guo-Long, et al.
Publicado: (2014)

Model-based Cost-effectiveness Analysis of Atorvastatin Drugs for Prevention of Cardiovascular Diseases in Iran
por: Jabbari, Alireza, et al.
Publicado: (2020)

Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease
por: Kobayashi, Junji
Publicado: (2022)

Tongxinluo Capsule Combined with Atorvastatin for Coronary Heart Disease: A Systematic Review and Meta-Analysis
por: Liu, Qiao, et al.
Publicado: (2021)

Cholesteryl Ester Transfer Protein Gene and Effectiveness of Lipid Lowering of Atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2010)

Comparative Study of Ezetimibe and Atorvastatin Alone and in Combination on Lipid Profile in Rats
por: Prasad, Anju, et al.
Publicado: (2013)

Effects of atorvastatin on porcine aqueous humour outflow and trabecular meshwork cells
por: Cong, Lin, et al.
Publicado: (2018)

Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination
por: Aslam, Farhan, et al.
Publicado: (2009)

ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk
Publicado: (2011)

Atorvastatin Inhibits High-Fat Diet-Induced Lipid Metabolism Disorders in Rats by Inhibiting Bacteroides Reduction and Improving Metabolism
por: Li, Huimin, et al.
Publicado: (2022)

Atorvastatin downregulates HSP22 expression in an atherosclerotic model in vitro and in vivo
por: Chen, Qi, et al.
Publicado: (2019)

Atorvastatin treatment does not abolish inflammatory mediated cardiovascular risk in subjects with chronic kidney disease
por: Hoogeveen, Renate M., et al.
Publicado: (2021)

Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin
por: Richard Hobbs, FD
Publicado: (2007)

Comprehensive Study of Atorvastatin Nanostructured Lipid Carriers through Multivariate Conceptualization and Optimization
por: Ghanem, Heba A., et al.
Publicado: (2021)

Hypolipidemic Activity of Olive Oil-Based Nanostructured Lipid Carrier Containing Atorvastatin
por: Elsewedy, Heba S., et al.
Publicado: (2022)

Comparison of lipid profiles and inflammation in pre- and post-menopausal women with cerebral infarction and the role of atorvastatin in such populations
por: Zhang, Jinhong, et al.
Publicado: (2018)

Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease
por: Visconti, Luca, et al.
Publicado: (2016)

Hypoglycaemia, Abnormal Lipids, and Cardiovascular Disease among Chinese with Type 2 Diabetes
por: Li, Yijun, et al.
Publicado: (2015)

Effects of atorvastatin on serum lipids, serum inflammation and plaque morphology in patients with stable atherosclerotic plaques
por: GUO, SUXIA, et al.
Publicado: (2012)

Recent advances in preventing cardiovascular disorders by managing lipid levels
por: Olsson, Anders G
Publicado: (2010)

Atorvastatin Restores PPARα Inhibition of Lipid Metabolism Disorders by Downregulating miR-21 Expression to Improve Mitochondrial Function and Alleviate Diabetic Nephropathy Progression
por: Xiang, Jiayi, et al.
Publicado: (2022)

Atorvastatin reduces cerebral vasospasm and infarction after aneurysmal subarachnoid hemorrhage in elderly Chinese adults
por: Chen, Junhui, et al.
Publicado: (2020)

Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial
por: Kimura, Genjiro, et al.
Publicado: (2016)

ANGPTL4 variants and their haplotypes are associated with serum lipid levels, the risk of coronary artery disease and ischemic stroke and atorvastatin cholesterol-lowering responses
por: Yang, Qian, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8jqj3b2170lponmh4gor9ai79a